EN DE
STOCK COMPARISON

Peoplelogy Berhad vs Fredun Pharmaceuticals: Fair Value & Quality

Both stocks run through our valuation models. Here is how Peoplelogy Berhad (0356) and Fredun Pharmaceuticals (FREDUN) compare, as of Aug 11, 2026.

As of Aug 11, 2026, Fair Value Calculator sees Fredun Pharmaceuticals as the more attractively valued of the two: Peoplelogy Berhad trades at MYR 0.22 versus a fair value of MYR 0.08 (-64%), while Fredun Pharmaceuticals trades at ₹1,218 versus ₹2,155 (+77%).
Peoplelogy Berhad
0356.KLSE · MYR · Financials
-64%
upside to fair value
overvalued
PriceMYR 0.22
Fair ValueMYR 0.08
Quality51/100
Fredun Pharmaceuticals
FREDUN.BSE · INR · Healthcare
+77%
upside to fair value
undervalued
Price₹1,218
Fair Value₹2,155
Quality33/100

Head-to-head numbers

Green value = the better side for that row (for valuation multiples: lower = cheaper).

Peoplelogy BerhadFredun Pharmaceuticals
Valuation
21.5×P/E (TTM)42.2×
0.72×P/S (TTM)2.23×
0.64×P/B5.03×
12.5×EV/EBITDA15.5×
1.0%Dividend yield0.0%
MYR 0.23Dividend per share₹0.70
Profitability
-5%Net margin5%
-3%Operating margin12%
0%Return on equity16%
9%Return on assets9%
Growth
9%Revenue growth (YoY)27%
9.4%Avg. growth/yr (3Y)32.2%
Avg. growth/yr (5Y)36.9%
Balance & size
0.06×Debt / equity0.20×
$22MMarket cap$149M
healthyGrowth qualityexpensive

Even match: 6 to 6 metric wins.

Dash = not meaningfully computable, for example with negative equity.

Quality in detail

The quality score, broken down into the same factor families as on the stock page, 0 to 100 per family.

Peoplelogy Berhadof which business quality 57 · market factors 29 Fredun Pharmaceuticalsof which business quality 35 · market factors 44
ProfitabilityMargins and returns on capital today
33
48
Quality GrowthAre margins and returns improving?
10
73
CashflowEarnings quality: real cash, not paper profit
97
5
Fin. StrengthBalance sheet, leverage, solvency risk
70
57
InvestmentDisciplined investing over empire-building
30
16
Low VolatilityCalm price path (market factor)
15
43
MomentumPrice trend over the last 3–12 months (market factor)
35
39
52W MomentumDistance to the 52-week high (market factor)
35
54
Net IssuanceBuybacks instead of dilution
82
7

What the models say

The median fair value (base case) per model family, each in the currency of its trading venue. Green = above the current price, red = below.

Peoplelogy Berhad

DCF ModelsMYR 0.11
Dividend DiscountMYR 0.11
Asset-BasedMYR 0.06
Growth DCFMYR 0.23
Economic ProfitMYR 0.04

8 of 9 models see the stock below the current price.

Fredun Pharmaceuticals

Earnings-Based₹1,942
Multiples₹1,723
Asset-Based₹345
Economic Profit₹1,854
Growth Earnings₹2,535

5 of 14 models see the stock below the current price.

Scenario ranges

From our cautious bear case to the optimistic bull case. The white tick is the current price: left of fair value means room to run.

Peoplelogy Berhad
Bear MYR 0.06Fair Value MYR 0.08Bull MYR 0.10
MYR 0.22 = current price (white tick)
Fredun Pharmaceuticals
Bear ₹1,509Fair Value ₹2,155Bull ₹2,802
₹1,218 = current price (white tick)

Compare two other stocks

Tap a field and type again, ticker or company name.

Free, no sign-up

Ranked within their sector

Where each stock sits within its sector peer group. Band = middle 50% of peers, tick = median, dot = this stock.

Peoplelogy Berhad · Financials

Quality score51 · below median
Fair value upside-64% · bottom 25%

Fredun Pharmaceuticals · Healthcare

Quality score33 · bottom 25%
Fair value upside+77% · Top 25%

Bottom line

As of Aug 11, 2026, Fair Value Calculator sees Fredun Pharmaceuticals as the more attractively valued of the two: Peoplelogy Berhad trades at MYR 0.22 versus a fair value of MYR 0.08 (-64%), while Fredun Pharmaceuticals trades at ₹1,218 versus ₹2,155 (+77%).

Peoplelogy Berhad has the higher quality score (51/100).

See the full analysis →

More comparisons

Popular match-ups from the same sectors, all with fair value and quality score.

Free · Top-25 report

See the undervalued quality stocks every month

Just your email for the monthly Top-25 report of the most undervalued quality stocks, with fair value, quality and price target. Plus 14 days of Pro to try, no card.

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.

A model-based valuation snapshot from 21 models. Values change with price and fundamentals; the date shown above applies.